Viracta
Viracta is a Healthcare & Life Sciences startup based in Israel, most recent round Series B, 1 tracked investor.
About Viracta
Viracta is a startup based in Israel. Its most recent tracked round is Series B. Brouky classifies it under Healthcare & Life Sciences. Brouky records 1 investor associated with the company.
Viracta develops precision oncology therapies for virally associated cancers, using its investigational drug Natinostat to induce Epstein–Barr virus gene expression which, in combination with antiviral valganciclovir, leads to targeted cancer cell death. The treatment is currently being tested in clinical studies for EBV-positive lymphomas and solid tumors.
Explore Viracta's full profile on Brouky
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.